dual PD-L1 checkpoint inhibitor/TLR7/8 agonist (Avacta)

N/A

Report date: 2025/01/26 18:33:47

Base Information

Drug Namedual PD-L1 checkpoint inhibitor/TLR7/8 agonist (Avacta)
Drug Alias Nameanti-PD-L1/TLR7/8 agonist conjugate (Avacta)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionToll like receptor 7 agonistsProgrammed death-ligand 1 blockersToll like receptor 8 agonists
TargetsToll like receptor 8Toll like receptor 7Programmed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvacta Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAvacta Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A